San Diego, CA — 01/11/2018 — An investigation was announced for investors in NASDAQ:RXDX shares over the takeover of Ignyta Inc by Roche for $27.00 per share.
Investors who purchased shares of Ignyta Inc (NASDAQ:RXDX) and currently hold any of those NASDAQ:RXDX shares have certain options and should contact the Shareholders Foundation at [email protected] or call 858-779-1554.
The investigation by a law firm concerns whether certain officers and directors of Ignyta Inc breached their fiduciary duties owed to NASDAQ:RXDX investors in connection with the proposed acquisition.
San Diego, CA based Ignyta, Inc. is a biotechnology company focused on precision medicine in oncology. On December 22, 2017, Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.00 per share in an all-cash transaction.
However, given that at least one analyst has set the high target price for NASDAQ:RXDX shares at $31.00 per share, the investigation concerns whether the offer is unfair to NASDAQ:RXDX stockholders. More specifically, the investigation concerns whether the Ignyta Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
Those who are current investors in Ignyta Inc (NASDAQ:RXDX) shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego
Powered by WPeMatico